Results 191 to 200 of about 55,011 (304)

Artificial lipidation of proteins and peptides: from mechanism to clinical applications

The FEBS Journal, EarlyView.
Artificial lipidation transforms protein and peptide therapeutics by attaching fatty acid chains through reversible or permanent chemical strategies. This biomimetic approach delivers four key therapeutic advantages: extended circulation times (enabling weekly instead of daily dosing), alternative administration routes including oral delivery, precise ...
Jiaming Mu, Emily Vong, Sheiliza Carmali
wiley   +1 more source

Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement [PDF]

Kariem El‐Boghdadly, Jugdeep Dhesi, Philippa Fabb, Nicholas Levy, Dileep N. Lobo, Andrew McKechnie, Омар Мустафа, Philip Newland‐Jones, Anil Patel, Dimitri J. Pournaras, Ken Clare, Ketan Dhatariya   +11 more
openalex   +1 more source

Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. [PDF]

PLoS Med
Chao AM, Gilden A, Wadden TA.
europepmc   +1 more source

Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists [PDF]

John W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan   +2 more
openalex   +1 more source

Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis

, 2023
Tzu‐Lin Yeh, Ming-Chieh Tsai, Wen-Hsuan Tsai, Yu‐Kang Tu, Kuo‐Liong Chien   +4 more
openalex   +2 more sources

Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis [PDF]

Arveen Shokravi, Jayant Seth, G.B.John Mancini   +2 more
openalex   +1 more source

Semaglutide—the “new kid on the block” in the field of glucagon-like peptide-1 receptor agonists? [PDF]

, 2017
Cristian Guja, Rucsandra Dănciulescu Miulescu   +1 more
openalex   +1 more source

The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition. [PDF]

Int J Mol Sci
Chrysavgis L, Mourelatou NG, Koloutsou ME, Rozani S, Cholongitas E.   +4 more
europepmc   +1 more source

Effect of switching from intermittently scanned continuous glucose monitoring to FreeStyle Libre 2 with real‐time continuous glucose monitoring and alert functionality

Journal of Diabetes Investigation, EarlyView.
Transitioning from FSL to FSL2 with rtCGM function improved sensor usage and glycemic control, particularly in patients with Type 1 diabetes. The duration required for improvement in continuous glucose monitoring‐related parameters varied by diabetes type, with early improvements observed in Type 1 diabetes and gradual improvements in Type 2 diabetes ...
Keiji Sugai, Junko Sasaki, Gakuyuki Tomizawa, Ryo Suzuki   +3 more
wiley   +1 more source

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer? [PDF]

Iskandar Idris
openalex   +1 more source